GSK-1795091
- Generic Name
- GSK-1795091
Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Neoplasms
- Interventions
- First Posted Date
- 2018-02-27
- Last Posted Date
- 2023-05-03
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 54
- Registration Number
- NCT03447314
- Locations
- 🇪🇸
GSK Investigational Site, Barcelona, Spain
A Phase I, 2-part (Part 1 Being a Single Dose Escalation and Part 2, a Parallel Group) Study of Toll-like Receptor (TLR4) Agonist (GSK1795091) in Healthy Subjects
- First Posted Date
- 2016-06-14
- Last Posted Date
- 2020-11-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 42
- Registration Number
- NCT02798978
- Locations
- 🇩🇪
GSK Investigational Site, Berlin, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath